ABEO Abeona Therapeutics

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Company profile
Ticker
ABEO
Exchange
Website
CEO
Jeffrey Davis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ACCESS PHARMACEUTICALS INC, CHEMEX PHARMACEUTICALS INC, PLASMATECH BIOPHARMACEUTICALS INC
SEC CIK
Corporate docs
IRS number
830221517
ABEO stock data
()
News
Abeona Therapeutics Q4 EPS $(0.17) Up From $(0.30) YoY, Sales $3.00M
24 Mar 21
33 Stocks Moving in Friday's Pre-Market Session
26 Feb 21
10 Stocks Going Crazy Today On No News, Thursday, Feb. 25, 2021 (Via Benzinga Pro's Movers Tool)
25 Feb 21
12 Health Care Stocks Moving In Thursday's Intraday Session
25 Feb 21
12 Health Care Stocks Moving In Friday's After-Market Session
19 Feb 21
Press releases
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
25 Mar 21
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
24 Mar 21
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
23 Mar 21
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
22 Mar 21
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
22 Feb 21
Investment data
Securities sold
Number of investors
Calendar
24 Mar 21
18 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.57M | 13.57M | 13.57M | 13.57M | 13.57M | 13.57M |
Cash burn (monthly) | (positive/no burn) | 9.73M | 4.83M | 6.79M | 536.67K | 2.92M |
Cash used (since last report) | n/a | 35.22M | 17.47M | 24.55M | 1.94M | 10.56M |
Cash remaining | n/a | -21.65M | -3.9M | -10.98M | 11.63M | 3.01M |
Runway (months of cash) | n/a | -2.2 | -0.8 | -1.6 | 21.7 | 1.0 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 21 | Carr Edward | Common stock | Sell | Dispose S | No | Yes | 1.7956 | 35,000 | 62.85K | 191,291 |
1 Apr 21 | Carr Edward | Common stock | Sell | Dispose S | No | Yes | 1.8521 | 20,445 | 37.87K | 226,291 |
31 Mar 21 | Michael Amoroso | Common stock | Sell | Dispose S | No | Yes | 1.8701 | 45,409 | 84.92K | 650,046 |
19 Mar 21 | Michael Amoroso | Common stock | Grant | Aquire A | No | No | 0 | 250,000 | 0 | 695,455 |
19 Mar 21 | Michael Amoroso | Stock Option Common Stock | Grant | Aquire A | No | No | 2.18 | 500,000 | 1.09M | 500,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners |
Shares | Value |
---|
Financial report summary
?Competition
Soligenix • Jazz Pharmaceuticals • Alder Biopharmaceuticals • Synedgen • Galera Therapeutics • uniQure • Regenxbio • Voyager Therapeutics • Editas Medicine • CRISPR TherapeuticsContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AAA, absent, accommodate, adulterated, Aid, Alto, ambit, Amoroso, ANTIDILUTIVE, apparent, attest, bill, bioreactor, black, box, boxed, branch, bronchial, brought, Bruckner, capita, cDNA, chance, clarity, communicable, Condensed, congregating, controversy, corneal, counterfeit, credible, CRL, custody, danger, deadline, Dear, declaratory, Dermatology, detention, diarrhea, die, disagree, disbursed, disfiguring, disregard, donor, DQSA, draft, drop, EC, economy, embedded, embezzling, episode, ester, faith, fault, filer, filtered, fluorescent, forgiven, fovea, fused, fusing, gather, gave, GDP, George, Germany, gradually, green, grown, harvested, helper, heterogeneity, HHS, Hirsch, home, Hull, impractical, improperly, inaccurate, inactive, inconclusive, ineligible, inevitable, ingredient, Inline, intentionally, Interactive, interface, intermittent, intervene, Journal, justly, lattice, laying, lender, likewise, linear, loan, lowest, Mann, master, mechanistically, media, Michael, Migausky, MMA, moderate, mortgage, mutual, nasal, navigating, necessitate, neurodevelopmental, nil, noncompliance, notwithstanding, novo, nurse, obstructing, OECD, offense, openly, ophthalmic, Orphanet, outer, outweigh, owe, Page, Palo, pandemic, passed, pause, paused, Paycheck, PBM, PDMA, penetrated, pharmacy, photoreceptor, pigmented, plasmid, plausible, PMA, Poor, postpone, postponed, PPP, predicated, preempted, premarket, prioritize, prolonged, prudent, qualification, quantity, quarantine, qui, reassessing, redirected, redundancy, regain, reinstituting, Relief, remote, renegotiate, repay, repricing, resumed, resuming, reveal, revoked, route, running, salt, SBA, searchable, SGSH, shareholder, Shawn, shortage, shorter, sixty, starter, stealing, sum, surface, survey, tam, Taysha, temporarily, thought, timepoint, Tomasello, tracing, training, transient, trick, triple, true, truth, turnover, unanimously, unapproved, unexercised, unfit, unforeseen, unforgiven, untrue, unvested, variant, verify, veterinary, VIITALTM, virtual, vomiting, White, workforce
Removed:
administering, Alvino, AMAG, amortizing, behavior, budget, buildup, burn, called, Chairman, collateral, collectible, commitment, correct, cumulative, detect, devoted, digest, Donald, doubtful, EBMRF, EBRP, eventual, fatty, Finland, graph, historic, HS, index, inflation, intrathecal, July, Junior, Leland, lesser, lysosome, MACM, Mark, match, mid, Miller, month, MPSIIIA, MuGard, NCL, NDA, Newfoundland, Norgine, northern, Obama, onset, originally, placement, poorly, President, prohibited, realizable, recalculated, recapitulate, recycle, Reorganization, Southern, speech, suggesting, Sweden, symptomatic, tagged, tenant, text, Timothy, Trump, unamortized, unqualified, view, week
Financial reports
10-K
2020 FY
Annual report
24 Mar 21
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
16 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
10 May 19
10-K
2018 FY
Annual report
18 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18
Current reports
8-K
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
30 Mar 21
8-K
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
24 Mar 21
8-K
Departure of Directors or Certain Officers
23 Mar 21
8-K
Regulation FD Disclosure
12 Feb 21
8-K
Departure of Directors or Certain Officers
1 Feb 21
8-K
Clinical trial amendment successfully completed for co-primary endpoints
25 Jan 21
8-K
Departure of Directors or Certain Officers
17 Nov 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Nov 20
8-K
Abeona Therapeutics Reports Third Quarter Financial Results
9 Nov 20
8-K
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
30 Oct 20
Registration and prospectus
S-8
Registration of securities for employees
21 May 20
424B5
Prospectus supplement for primary offering
23 Dec 19
25-NSE
Exchange delisting
20 Dec 19
424B5
Prospectus supplement for primary offering
19 Dec 19
424B5
Prospectus supplement for primary offering
17 Aug 18
S-3/A
Shelf registration (amended)
1 Jun 18
S-3
Shelf registration
11 May 18
RW
Registration withdrawal request
15 Mar 18
S-8
Registration of securities for employees
13 Nov 17
424B5
Prospectus supplement for primary offering
16 Oct 17
Proxies
DEF 14A
Definitive proxy
9 Apr 21
PRE 14A
Preliminary proxy
30 Mar 21
PX14A6G
Letter to shareholders
29 Apr 20
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
10 Apr 20
DEF 14A
Definitive proxy
11 Apr 19
DEF 14A
Definitive proxy
9 Apr 18
DEF 14A
Definitive proxy
10 Apr 17
DEF 14A
Definitive proxy
5 Apr 16
DEF 14A
Definitive proxy
6 Apr 15
Other
UPLOAD
Letter from SEC
23 Sep 19
CORRESP
Correspondence with SEC
19 Sep 19
UPLOAD
Letter from SEC
17 Sep 19
CORRESP
Correspondence with SEC
19 Aug 19
UPLOAD
Letter from SEC
5 Aug 19
CT ORDER
Confidential treatment order
3 Apr 19
EFFECT
Notice of effectiveness
8 Jun 18
EFFECT
Notice of effectiveness
2 May 17
UPLOAD
Letter from SEC
30 Jan 17
CORRESP
Correspondence with SEC
24 Jan 17
Ownership
3
ABEONA THERAPEUTICS / Mark Alvino ownership change
6 Apr 21
3
ABEONA THERAPEUTICS / Faith L. Charles ownership change
6 Apr 21
4
ABEONA THERAPEUTICS / EDWARD CARR ownership change
5 Apr 21
4
ABEONA THERAPEUTICS / Michael Amoroso ownership change
2 Apr 21
4
ABEONA THERAPEUTICS / Michael Amoroso ownership change
23 Mar 21
4
ABEONA THERAPEUTICS / Steven H Rouhandeh ownership change
19 Mar 21
4
ABEONA THERAPEUTICS / Michael Amoroso ownership change
3 Mar 21
4
ABEONA THERAPEUTICS / EDWARD CARR ownership change
3 Mar 21
4
ABEONA THERAPEUTICS / Paul Elliot Mann ownership change
23 Feb 21
4
ABEONA THERAPEUTICS / Todd Wider ownership change
23 Feb 21
Transcripts
2020 Q4
Earnings call transcript
25 Mar 21
2019 Q2
Earnings call transcript
12 Aug 19
2019 Q1
Earnings call transcript
14 May 19
2018 Q4
Earnings call transcript
19 Mar 19
2018 Q3
Earnings call transcript
12 Nov 18
2018 Q2
Earnings call transcript
10 Aug 18
2018 Q1
Earnings call transcript
14 May 18
2017 Q4
Earnings call transcript
27 Mar 18
2017 Q3
Earnings call transcript
20 Nov 17
Reddit threads
$ATOS - Currently trading 45% under recent Direct Offering from $2.88 to $1.75
13 Apr 21
Daily Plays - April 13, 2021
13 Apr 21
THE LOUNGE: thoughts, noob stuff, low effort, brokers, zero DD, non pennies - March 24, 2021
23 Mar 21
Daily Discussion Thread - March 22nd, 2021
22 Mar 21
Daily Discussion Thread - March 19th, 2021
19 Mar 21
Daily Discussion Thread - March 15th, 2021
15 Mar 21
Daily Discussion Thread - March 12th, 2021
12 Mar 21
Dips today??
4 Mar 21
Daily Plays - March 03, 2021
3 Mar 21
What strategy has been the most successful to you?
1 Mar 21